MX387719B - Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos. - Google Patents

Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos.

Info

Publication number
MX387719B
MX387719B MX2018012654A MX2018012654A MX387719B MX 387719 B MX387719 B MX 387719B MX 2018012654 A MX2018012654 A MX 2018012654A MX 2018012654 A MX2018012654 A MX 2018012654A MX 387719 B MX387719 B MX 387719B
Authority
MX
Mexico
Prior art keywords
alcoholic
nafld
nash
liver disease
fatty liver
Prior art date
Application number
MX2018012654A
Other languages
English (en)
Inventor
Malti Nikrad
Stephen Alaric Williams
Stuart G Field
Original Assignee
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Operating Co Inc filed Critical Somalogic Operating Co Inc
Publication of MX387719B publication Critical patent/MX387719B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos, composiciones y kits para determinar si un sujeto tiene la enfermedad del hígado graso no alcohólico (NAFLD). También se proporcionan métodos, composiciones y kits para determinar si un sujeto tiene esteatosis no alcohólica. También se proporcionan métodos, composiciones y kits para determinar si un sujeto tiene esteatohepatitis no alcohólica (NASH).
MX2018012654A 2013-03-15 2014-03-10 Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos. MX387719B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787967P 2013-03-15 2013-03-15
PCT/US2014/022547 WO2014150198A2 (en) 2013-03-15 2014-03-10 Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
MX387719B true MX387719B (es) 2025-03-18

Family

ID=50483498

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012654A MX387719B (es) 2013-03-15 2014-03-10 Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos.
MX2015011756A MX360140B (es) 2013-03-15 2014-03-10 Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015011756A MX360140B (es) 2013-03-15 2014-03-10 Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos.

Country Status (9)

Country Link
US (3) US9612248B2 (es)
EP (3) EP3296747B1 (es)
CN (2) CN108957006B (es)
BR (1) BR122019026188B1 (es)
DK (1) DK3296747T3 (es)
ES (3) ES2662108T3 (es)
MX (2) MX387719B (es)
WO (1) WO2014150198A2 (es)
ZA (1) ZA201506441B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3584327A1 (en) 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US20160289762A1 (en) 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
US9612248B2 (en) * 2013-03-15 2017-04-04 Somalogic, Inc. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
MX386778B (es) 2015-03-09 2025-03-19 Intekrin Therapeutics Inc Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia.
JP2018518169A (ja) * 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
KR102687249B1 (ko) * 2016-02-08 2024-07-22 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간 질환 (nafld)과 비알코올성 지방간염 (nash) 생물마커 및 이들의 용도
US20190071795A1 (en) * 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
CN107630084A (zh) * 2016-07-18 2018-01-26 昆山德诺瑞尔生物科技有限公司 非酒精性脂肪性肝炎的多基因组合检测试剂盒
JP6893406B2 (ja) * 2016-10-19 2021-06-23 日本化薬株式会社 Ｎａｓｈやｎａｆｌｄの進展度の検査方法及び炎症疾患や癌の検査方法
JP7111322B2 (ja) * 2016-12-02 2022-08-02 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
US12372530B2 (en) * 2017-11-15 2025-07-29 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
EP3716986A4 (en) 2017-12-01 2022-02-09 Cornell University NANOPARTICLES AND VARIOUS EXOSOME SUBSETS FOR CANCER DETECTION AND TREATMENT
AU2019367010A1 (en) * 2018-10-26 2021-06-17 Molecular Stethoscope, Inc. Disease stratification of liver disease and related methods
GB2612911B (en) 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
CN110786834B (zh) * 2019-12-09 2022-04-05 中电健康云科技有限公司 一种基于舌象特征和bmi指数的脂肪肝预测模型
CN115023615A (zh) * 2020-01-10 2022-09-06 私募蛋白质体操作有限公司 确定葡萄糖耐量减低的方法
JP7766605B2 (ja) * 2020-02-10 2025-11-10 ソマロジック オペレーティング カンパニー インコーポレイテッド 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
WO2022114887A1 (ko) * 2020-11-27 2022-06-02 국립암센터 통합전사체분석 기반 만성 간질환 진단용 복합마커 및 이의 용도
EP4352743A1 (en) * 2021-06-09 2024-04-17 Université catholique de Louvain System and method for determining a risk of having or developing steatohepatitis and/or a complication thereof
CN118547066B (zh) * 2024-07-30 2024-11-19 上海交通大学医学院附属仁济医院 一种非酒精性脂肪性肝炎的诊断试剂盒及诊断系统

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU2004251654A1 (en) * 2003-06-02 2005-01-06 Icoria, Inc. Use of genes differentially expressed during aging of liver for treatment and diagnosis
EP2021512A4 (en) 2006-05-08 2009-08-05 Tethys Bioscience Inc SYSTEMS AND METHODS FOR DEVELOPING DIAGNOSTIC TESTS BASED ON BIOMARKER INFORMATION FROM EXISTING CLINICAL SAMPLE ASSEMBLIES
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
MX344253B (es) 2007-07-17 2016-12-09 Somalogic Inc Metodo para generar aptameros con constantes de disociacion mejoradas.
EP2313782B1 (en) 2008-07-03 2012-08-29 One Way Liver Genomics, S.L. Proteomic fingerprint for the diagnosis of non-alcoholic steatohepatitis (nash) and/or steatosis
US20100124548A1 (en) * 2008-10-29 2010-05-20 University Of Oulu Pharmaceutical product
EP2496944A2 (en) * 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA2809282C (en) 2010-09-27 2017-09-12 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
CN104812913B (zh) * 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
US9612248B2 (en) * 2013-03-15 2017-04-04 Somalogic, Inc. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof

Also Published As

Publication number Publication date
CN108957006A (zh) 2018-12-07
ZA201506441B (en) 2019-07-31
EP3660512A1 (en) 2020-06-03
BR122019026188A8 (pt) 2022-10-18
MX2015011756A (es) 2016-01-14
US20170227550A1 (en) 2017-08-10
MX360140B (es) 2018-10-24
CN105143887A (zh) 2015-12-09
WO2014150198A2 (en) 2014-09-25
WO2014150198A3 (en) 2014-12-18
BR112015021992A2 (pt) 2017-07-18
BR122019026188B1 (pt) 2024-01-02
ES2986657T3 (es) 2024-11-12
EP3296747B1 (en) 2020-01-08
EP2972386B1 (en) 2018-01-10
DK3296747T3 (da) 2020-03-30
CN108957006B (zh) 2021-07-27
EP3660512C0 (en) 2024-07-24
US9612248B2 (en) 2017-04-04
US20140303018A1 (en) 2014-10-09
ES2773999T3 (es) 2020-07-16
EP3660512B1 (en) 2024-07-24
HK1220251A1 (en) 2017-04-28
EP3296747A1 (en) 2018-03-21
ES2662108T3 (es) 2018-04-05
CN105143887B (zh) 2018-08-28
BR112015021992A8 (pt) 2019-12-03
BR122019026188A2 (es) 2017-07-18
US20180259537A1 (en) 2018-09-13
EP2972386A2 (en) 2016-01-20
US9945875B2 (en) 2018-04-17
US10359435B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
MX387719B (es) Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos.
CL2016002455A1 (es) Anticuerpos multiespecíficos.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
GEAP202114450A (en) Anti-tigit antibodies
HUE053457T2 (hu) Multispecifikus ellenanyag-konstrukciók
UY34601A (es) ?mezclas fungicidas de pirazol?.
EP4282983A3 (en) Compositions and methods for polynucleotide sequencing
MX387296B (es) Proliferacion ex vivo de celulas epiteliales.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2016012667A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
MX392040B (es) Estandares de antigeno prostatico y sus usos.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
EA201690263A1 (ru) Улучшенные способы получения перампанеля
IN2013MU01113A (es)
MX2017010901A (es) Colorantes de acido trisazo.
BR112017014842A2 (pt) composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
TH1601003614A (th) การทดสอบวินิจฉัยโรคซึ่งถูกปรับปรุงสำหรับแอนทิบอดี csfv
BR112018014842A2 (pt) biomarcadores de doenças hepática gordurosa não alcoólica (nafld) e esteato-hepatite não alcoólica (nash) e utilização dos mesmos
TWD162428S (zh) 鞋墊
TWD175566S (zh) 雪鏡
IES20140280A2 (en) Human targets II